Prevalence of patients with uncontrolled asthma despite high intensity treatment (NVL/GINA step 4/5) in Germany

Bergmann, K; Skowasch, Dirk; Timmermann, H; Lindner, Robert; Jc, Virchow; Schmidt, O; Koschel, Dirk; Heck, S; Milger, Katrin

doi:10.1055/s-0042-1747702

Cited by 1 publication

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study design and methods have been published previously. 4 , 5 The study was supported by an expert committee of pulmonologists from private practices and hospitals. In cooperation with GlaxoSmithKline, the methodology, patient cohorts, and data analyses were defined.…”

Section: Methodsmentioning

confidence: 99%

“…In 2019, around 54,000 GINA step 4/5 asthma patients in Germany still showed evidence of uncontrolled asthma (oral corticosteroid [OCS] and/or short-acting β2-agonist [SABA] overuse), as described in a recently published study; there have been with no major improvements over recent years. 4 , 5 Up to 15% of patients receiving step 4/5 treatment 2 are uncontrolled in some regions in Germany. 2 , 4 , 5 Only 12,000 patients treated according to GINA step 4/5 are currently receiving biologicals, which means there might be an opportunity for improvement.…”

Section: Introductionmentioning

confidence: 99%

“… 4 , 5 Up to 15% of patients receiving step 4/5 treatment 2 are uncontrolled in some regions in Germany. 2 , 4 , 5 Only 12,000 patients treated according to GINA step 4/5 are currently receiving biologicals, which means there might be an opportunity for improvement. 4 , 5 The objective of the current data analysis was to elucidate possible causes of this treatment gap.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Health Care Situation in the Treatment of Uncontrolled GINA Step 4/5 Patients in Germany

Timmermann¹,

Milger²,

Virchow³

et al. 2023

JAA

View full text Add to dashboard Cite

Purpose It has been estimated that, in 2019, 54,000 patients in Germany had uncontrolled GINA step 4/5 asthma. In the current study we analyzed which health care providers were involved in the management of these patients and their role in disease phenotyping. Patients and Methods The year 2019 was retrospectively analyzed using the IQVIA TM LRx, a longitudinal anonymized prescription database, and the electronic, anonymized medical records database, the IQVIA Disease Analyzer. Results Of 54,000 uncontrolled GINA step 4/5 asthma patients in Germany, 52% had consulted both general practitioners (GPs) and pulmonologists, and 48% were seen exclusively by a GP. Of these 54,000 patients, 45% were being prescribed and were thus overusing short-acting β2-agonists (SABAs) and oral corticosteroids (OCS) for ≥2 years, 26% for ≥3 years, and 16% for ≥4 years. In most regions, pulmonologists saw one of their uncontrolled GINA step 4/5 asthma patients per week. Laboratory tests from consultations with a GP were available for only 10% of patients referred to a pulmonologist. In 50% of uncontrolled asthma patients treated according to GINA step 4/5, these were initiated by the pulmonologist, and 34% received laboratory testing within the first year (in GINA step 4/5 asthma, the numbers are 20% and 18%, respectively). Conclusion Fifty percent of uncontrolled asthma patients treated according to GINA step 4/5 were regularly seen by pulmonologists, who performed most of the phenotyping confirming their importance in the management of severe, uncontrolled asthma in Germany. To understand treatment pathways for these patients, further studies are needed.

show abstract

Section: Methodsmentioning

confidence: 99%